Home › Lupus
Lupus clinical trials recruiting in the U.S.
73 studies for Lupus are recruiting participants at sites across the United States.
Lupus is an autoimmune disease that causes your immune system to attack your healthy tissues and cells. This can cause damage to many parts of your body.
Cities with the most studies
- New York City, NY18 studies
- Durham, NC12 studies
- Houston, TX12 studies
- Miami, FL10 studies
- Washington, DC10 studies
- Tampa, FL9 studies
- Philadelphia, PA9 studies
- Chicago, IL8 studies
- Boston, MA8 studies
- Clearwater, FL8 studies
- Los Angeles, CA8 studies
- Santa Monica, CA8 studies
- Charlotte, NC7 studies
- Buena Park, CA7 studies
- Plantation, FL7 studies
- San Diego, CA7 studies
- Oklahoma City, OK7 studies
- Memphis, TN7 studies
- Atlanta, GA6 studies
- Aurora, CO6 studies
- Cedar Rapids, IA6 studies
- Dallas, TX6 studies
- Hollywood, FL6 studies
- Syracuse, NY5 studies
- St. Louis, MO5 studies
- Orlando, FL5 studies
- Cicero, IL5 studies
- Jackson, TN5 studies
- Lake Charles, LA5 studies
- Fullerton, CA5 studies
- Cleveland, OH5 studies
- New Orleans, LA5 studies
- San Francisco, CA4 studies
- San Antonio, TX4 studies
- Coral Springs, FL4 studies
- Allen, TX4 studies
- Louisville, KY4 studies
- Charleston, SC4 studies
- Salt Lake City, UT4 studies
- Kansas City, KS4 studies
By state
- Alabama5 studies
- Arizona7 studies
- California27 studies
- Colorado8 studies
- District of Columbia5 studies
- Florida23 studies
- Georgia9 studies
- Illinois14 studies
- Indiana4 studies
- Iowa6 studies
- Kansas5 studies
- Kentucky4 studies
- Louisiana9 studies
- Maryland10 studies
- Massachusetts9 studies
- Michigan10 studies
- Minnesota5 studies
- Missouri8 studies
- Nebraska3 studies
- New Jersey6 studies
- New York26 studies
- North Carolina20 studies
- Ohio11 studies
- Oklahoma7 studies
- Pennsylvania13 studies
- South Carolina5 studies
- Tennessee13 studies
- Texas26 studies
- Utah4 studies
- Virginia4 studies
- Washington5 studies
Recently updated studies
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
RecruitingObservational study
Ages 18 to 120 · Women · Updated Sep 28, 2026 · NCT05567198A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT07607964A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 25, 2026 · NCT07430306CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RecruitingPhase 1/2
Ages 10 to 29 · All sexes · Updated Sep 24, 2026 · NCT06839976Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 18, 2026 · NCT05440422Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Sep 18, 2026 · NCT07201558Anifrolumab Pregnancy Study
RecruitingObservational study
Ages 18 to 130 · Women · Updated Sep 18, 2026 · NCT07049653A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
RecruitingPhase 2
Ages 16 to 70 · All sexes · Updated Sep 17, 2026 · NCT07328581Transcutaneous Vagus Nerve Stimulation in SLE
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06987565A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
RecruitingPhase 2
Ages 18 to 74 · All sexes · Updated Sep 17, 2026 · NCT07409181Study of Systemic Lupus Erythematosus
RecruitingObservational studyHealthy volunteers welcome
Ages 3 to 120 · All sexes · Updated Sep 16, 2026 · NCT00001372Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
RecruitingPhase 4
Ages 18 to 130 · Women · Updated Sep 16, 2026 · NCT06594068HEALTH Home Urinalysis Testing
Recruiting
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07823478A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Sep 15, 2026 · NCT06916806Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
RecruitingPhase 1
Ages 18 to 60 · All sexes · Updated Sep 14, 2026 · NCT06975787A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 14, 2026 · NCT07355218A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
RecruitingPhase 2
Ages 12 to 70 · All sexes · Updated Sep 14, 2026 · NCT07570862A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 11, 2026 · NCT07332481A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Sep 10, 2026 · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 10, 2026 · NCT05835310A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
RecruitingPhase 4
Ages 18 to 75 · All sexes · Updated Sep 9, 2026 · NCT06875960A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
RecruitingPhase 3
Ages 16 and older · All sexes · Updated Sep 4, 2026 · NCT06617325From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.